Zydus Cadila inks pact with Italy's SIFI to market intraocular lenses
Drug firm Zydus Cadila on Tuesday said the company has tied up with Italy-based ophthalmic firm SIFI to market intraocular lenses in India. SIFI's in30-04-2019
30-04-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Bosentan Tablets & Trientine Hydrochloride Capsules30-04-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus and SIFI from Italy announce marketing alliance to launch Innovative Intraocular Lenses in India30-04-2019
CADILA HEALTHCARE LTD. - 532321 - Confirmation With Regard To Large Corporate
Confirmation with regard to large corporate29-04-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Leflunomide Tablets USP.25-04-2019
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate18-04-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Acetazolamide for Injection17-04-2019
Zydus Cadila announces phase III clinical trials of Desidustat
Drug firm Zydus Cadila on Wednesday announced phase III clinical trials of Desidustat, an investigational new drug targeted at treating anaemia in n17-04-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Announces Phase 3 Trial of Desidustat in Non-Dialysis Dependent Chronic Kidney Disease (CKD) Patients with Anemia17-04-2019
Cadila Healthcare Ltd - 532321 - Shareholding for the Period Ended March 31, 2019
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here12-04-2019